Satellos Bioscience (MSLE) Beginning Cash Balance (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly Beginning Cash Balance came in at $9.8 million in Q1 2026, down 75.53% year-on-year from $40.1 million in Q1 2025, and down 75.53% on a QoQ basis from $40.1 million in Q1 2025.
Satellos Bioscience (MSLE) Beginning Cash Balance (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Beginning Cash Balance data on file, last reported at $9.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Satellos Bioscience | 175.69 Mn | 175.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.80 Mn |
| Mar 31, 2026 | 9.80 Mn |
| Mar 31, 2025 | 40.07 Mn |
| Mar 31, 2025 | 40.07 Mn |